Category
Biologics & Advanced Therapies
Modern targeted treatments for moderate-severe IBD
Tremfya vs Omvoh for Ulcerative Colitis: Which to Choose?
Tremfya and Omvoh are both IL-23 p19-selective biologics for moderate-to-severe ulcerative colitis, both newly approved for the indication. Omvoh gained UC approval in October 2023 based on LUCENT-1 and LUCENT-2. Tremfya gained UC approval in September 2024 based on QUASAR and ASTRO. Patients comparing these two within-class UC options often weigh induction flexibility, urgency outcomes, and maintenance dosing. This guide walks through the tremfya vs omvoh ulcerative colitis comparison.
Tremfya vs Omvoh for Crohn's Disease: Key Differences
Tremfya and Omvoh are both IL-23 p19-selective biologics for moderate-to-severe Crohn's disease, each newly approved for the indication. Tremfya gained Crohn's approval in March 2025 based on GALAXI-2 and GALAXI-3, with the GRAVITI trial supporting a fully subcutaneous induction option. Omvoh gained Crohn's approval in January 2025 based on VIVID-1. Patients comparing these two within-class options often weigh administration flexibility and active-comparator trial design. This guide walks through the tremfya vs omvoh crohn's comparison.
Tremfya vs Humira for Ulcerative Colitis: Which Is Right?
Tremfya and Humira are two biologics for moderate-to-severe ulcerative colitis that take fundamentally different mechanistic approaches. Humira is the established anti-TNF with more than a decade of UC experience. Tremfya is an IL-23 p19-selective biologic approved for UC in September 2024 based on the QUASAR and ASTRO trials, which uniquely offers both subcutaneous and intravenous induction pathways. UC patients choosing between these drugs weigh mechanism, administration flexibility, and long-term safety. This guide walks through the tremfya vs humira ulcerative colitis decision.
Tremfya vs Humira for Crohn's Disease: Key Differences
Tremfya and Humira represent two different eras in Crohn's biologic therapy. Humira is a fully human anti-TNF biologic that has been a Crohn's staple since 2007. Tremfya is an IL-23 p19-selective biologic that gained Crohn's approval in 2024 and uniquely offers both subcutaneous and intravenous induction pathways. Patients comparing these drugs often weigh mechanism, administration flexibility, and the strength of the available trial evidence. This guide walks through the tremfya vs humira crohn's decision.
Tremfya vs Entyvio for Ulcerative Colitis: A Comparison
Tremfya and Entyvio are two non-anti-TNF biologics for moderate-to-severe ulcerative colitis, each offering meaningful safety advantages over anti-TNFs through very different mechanisms. Tremfya is an IL-23 p19-selective biologic approved for UC in September 2024 based on the QUASAR and ASTRO trials. Entyvio is gut-selective and has been a UC option since 2014, with a head-to-head VARSITY trial showing superiority over adalimumab. Patients weighing these drugs often prioritize long-term safety or seek alternatives to anti-TNF therapy. This guide walks through the tremfya vs entyvio ulcerative colitis comparison.
Tremfya vs Entyvio for Crohn's Disease: How They Compare
Tremfya and Entyvio are two non-anti-TNF biologics for moderate-to-severe Crohn's disease, and patients often compare them when prioritizing safety or looking for alternatives to systemic TNF blockade. Tremfya is an IL-23 p19-selective biologic with strong endoscopic data from the GALAXI and GRAVITI trials. Entyvio is gut-selective and acts almost exclusively on the intestines. Both offer meaningful safety advantages over anti-TNFs, but they work through very different mechanisms. This guide walks through the tremfya vs entyvio crohn's comparison.
Stelara vs Remicade for Ulcerative Colitis: A Comparison
Stelara and Remicade are two commonly used biologics for moderate-to-severe ulcerative colitis, and both start with an intravenous infusion. Beyond that shared starting point, they work differently, have different safety profiles, and come with very different maintenance schedules. Patients typically weigh them when starting a first biologic, switching after anti-TNF failure, or looking at long-term infection risk. This guide walks through the evidence UC patients need to make an informed stelara vs remicade ulcerative colitis decision with their gastroenterologist.
Stelara vs Humira for Ulcerative Colitis: Key Differences
Stelara and Humira are two of the most common biologics discussed when ulcerative colitis patients are starting a first biologic or looking for a next step after losing response. Humira is a long-established anti-TNF. Stelara is an IL-12/23 blocker that arrived in UC much more recently. They work through different immune pathways, come with different dosing schedules, and differ meaningfully on safety. This guide walks through the evidence UC patients need to make an informed stelara vs humira ulcerative colitis decision with their gastroenterologist.
Skyrizi vs Tremfya for Ulcerative Colitis: Comparing IL-23s
Skyrizi and Tremfya are both IL-23 p19-selective biologics for moderate-to-severe ulcerative colitis. Skyrizi gained UC approval in June 2024 based on INSPIRE and COMMAND. Tremfya gained UC approval in September 2024 based on QUASAR and ASTRO. Patients comparing these two within-class UC options often weigh induction flexibility, maintenance dosing, and trial design. This guide walks through the skyrizi vs tremfya ulcerative colitis comparison.
Skyrizi vs Tremfya for Crohn's Disease: Which Is Right?
Skyrizi and Tremfya are both IL-23 p19-selective biologics for moderate-to-severe Crohn's disease, made by competing manufacturers (AbbVie and Johnson & Johnson). Both drugs belong to the same mechanism class and target the same cytokine subunit, so the skyrizi vs tremfya crohn's comparison often comes down to trial data, administration options, and maintenance convenience. This guide walks through the key differences to help you discuss the decision with your GI.
Skyrizi vs Stelara for Ulcerative Colitis: A Comparison
Skyrizi and Stelara are two interleukin-pathway biologics increasingly used for moderate-to-severe ulcerative colitis. Skyrizi gained UC approval in June 2024, joining Stelara in the IL-23 targeting category. The two drugs take meaningfully different approaches. Skyrizi blocks only IL-23. Stelara blocks both IL-12 and IL-23. For Crohn's, the SEQUENCE head-to-head trial showed Skyrizi's p19 selectivity outperformed Stelara on endoscopic endpoints, and UC patients often want to know whether similar logic applies to their disease. This guide walks through the current evidence and practical considerations for the skyrizi vs stelara ulcerative colitis decision.
Skyrizi vs Stelara for Crohn's Disease: SEQUENCE Trial Results
Skyrizi and Stelara are two interleukin-pathway biologics for moderate-to-severe Crohn's disease, and until recently the choice between them was largely mechanistic speculation. That changed with the SEQUENCE trial, a rare head-to-head randomized study that directly compared risankizumab (Skyrizi) with ustekinumab (Stelara) in Crohn's patients who had failed an anti-TNF. The results have reshaped how many gastroenterologists think about IL-23 targeting and have moved Skyrizi toward the front of the line for biologic-experienced Crohn's disease. This guide walks through the SEQUENCE findings and the practical decisions patients need to make with their GI.